Full Text:   <247>

CLC number: 

On-line Access: 2023-12-21

Received: 2023-07-11

Revision Accepted: 2023-12-05

Crosschecked: 0000-00-00

Cited: 0

Clicked: 269

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 1998 Vol.-1 No.-1 P.

http://doi.org/10.1631/jzus.B2300492


Immune checkpoint blockade for cancer therapy: current progress and perspectives


Author(s):  Hongying YE, Weijie LIAO, Jiongli PAN, Yin SHI, Qingqing WANG

Affiliation(s):  Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China; more

Corresponding email(s):   wqq@zju.edu.cn, yinshi@zju.edu.cn

Key Words:  Immune checkpoint blockade, Cancer immunotherapy, Tumor immune evasion, Immune normalization


Hongying YE, Weijie LIAO, Jiongli PAN, Yin SHI, Qingqing WANG. Immune checkpoint blockade for cancer therapy: current progress and perspectives[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .

@article{title="Immune checkpoint blockade for cancer therapy: current progress and perspectives",
author="Hongying YE, Weijie LIAO, Jiongli PAN, Yin SHI, Qingqing WANG",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2300492"
}

%0 Journal Article
%T Immune checkpoint blockade for cancer therapy: current progress and perspectives
%A Hongying YE
%A Weijie LIAO
%A Jiongli PAN
%A Yin SHI
%A Qingqing WANG
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2300492

TY - JOUR
T1 - Immune checkpoint blockade for cancer therapy: current progress and perspectives
A1 - Hongying YE
A1 - Weijie LIAO
A1 - Jiongli PAN
A1 - Yin SHI
A1 - Qingqing WANG
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2300492


Abstract: 
The dysfunction of anti-tumor immune responses is crucial for cancer progression. immune checkpoint blockade (ICB), which could potentiate T cell responses, is an effective strategy for the normalization of host anti-tumor immunity. In recent years, immune checkpoints, expressed on both tumor cells and immune cells, have been identified; some of them have exhibited potential druggability and have been approved by the Food and Drug Administration (FDA) for clinical treatments. However, the limited responses and immune-related adverse events (irAEs) cannot be ignored. This review outlines the development and applications of ICBs, potential strategies for overcoming resistance, and future directions for ICB-based cancer immunotherapy.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE